[Newsmp] Last year, HanAll Biopharma, JW Pharmaceutical and Chong Kun Dang Pharmaceutical were the top 100 stocks in terms of stock price increase among the 930 listed stocks on the KOSPI market.
According to the Korea Exchange, HanAll Biopharma ranked 15th on the stock price leaderboard in 2023 with a nearly 150% increase.
Following HanAll Biopharma's lead, JW Pharmaceutical and Chong Kun Dang Pharmaceutical also saw significant stock price increases of nearly 100% and 67.1%, respectively, ranking 29th and 58th.
Including HanAll Biopharma, JW Pharmaceutical, and Chong Kun Dang Pharmaceutical, a total of 11 pharmaceutical stocks (including preferred shares, pharmaceutical index constituent stocks, and holding company stocks) clinched spots in the top 200 based on share price surge in the KOSPI market.
Ilsung Pharmaceutical soared 39.9% to 115th, and Boryung Pharma climbed 31.2% to 145th, entering the top 150. Yuhan secured 173rd with 25.7%, followed by Celltrion (25.6%, 174th), Kwang Dong Pharmaceutical (24.7%, 181st), JW Holdings (22.8%, 191st), Yuhan Corp. Pfd. Series 1 (21.9%, 196th), and Hanmi Science (20.8%, 199th).
Following the 11 companies, pharmaceutical stocks with double-digit stock price increases entered the top 300, with Hanmi Pharmaceutical rising 20.6% to 202nd, Korea United Pharm. 18.7% to 213rd, Dong-A ST 15.9% to 234th, Kukje Pharma 12.7% to 267th, Dong Wha Pharm 11.7% to 278th, and Dong Wha Pharm 10.9% to 286th.
The stock prices of JW Pharmaceutical Corp. Pfd. Series 1, JW Life Science, Daewoong, and CKD Bio also rose slightly from the beginning of the year, but the stock prices of the remaining 39 pharmaceutical stocks fell during the same period.
